Form 4: C4 Therapeutics Director Acquires Stock Options

C4 Therapeutics Director Donna Roy Grogan acquired 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027, or the next annual meeting.

Summary

• Donna Roy Grogan, a Director at C4 Therapeutics, Inc., acquired 62,000 stock options.
• The options have an exercise price of $4.25 per share.
• These options are set to vest and become exercisable in full on the earlier of June 24, 2027, or the next annual meeting of the Issuer's stockholders, provided Grogan remains a Board member.
• The transaction date was June 24, 2026, and the filing date was June 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common practice and does not inherently signal a significant positive or negative development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The exercise price of $4.25 suggests a potential for significant upside if the stock price increases.

Risks

• The vesting schedule is tied to continued service, meaning the options may not become fully exercisable if the director's tenure ends prematurely.
• The value of the options is contingent on the future stock performance of C4 Therapeutics.

Future Outlook

The stock options are exercisable upon vesting, which is scheduled for June 24, 2027, or the next annual meeting, indicating a medium-term outlook for potential share acquisition by the director.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to incentivize and retain key personnel, aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively if it aligns management's interests with long-term shareholder value creation. However, it also represents potential future dilution if exercised.

Next Steps

• The stock options will vest and become exercisable on the specified vesting date, subject to continued service.
• The director may choose to exercise these options if the stock price exceeds the $4.25 exercise price.

Key Dates

Keywords

C4 Therapeutics, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, SEC Filing, CCCC